Combinative growth-inhibitory effects of interferon-alpha and Doxorubicin on multidrug-resistant tumor-cell lines
V Leonardi1, N Borsellino, M Crescimanno
1UNIV PALERMO,POLICLIN PAOLO GIACCONE,INST PHARMACOL,I-90127 PALERMO,ITALY.
Abstract:
The antiproliferative effects of interferon-alpha (IFN-alpha) and of its combination with doxorubicin (DXR) were studied on three tumor cell lines, the mouse B16 melanoma and Friend erythroleukemia and the human K562 erythroleukemia, both as DXR-sensitive (B16, FLC, K562) and resistant (B16-DXR, FLC-DXR, K562-DXR) variants; the latter lines were endowed with typical multidrug resistance (MDR). Growth inhibition by IFN-alpha was greater in B16-DXR and FLC-DXR than in their chemosensitive counterparts and was superimposable in K562 and K562-DXR. On the other hand, the combination of IFN-alpha and DXR turned out to be merely additive in B16, B16-DXR, K562 and K562-DXR; it was synergistic in FLC and antagonistic in FLC-DXR. Our results and those of others seem to indicate that synergy between IFN-alpha and DXR may occur rarely in MDR cells.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Treatment Resistant Cancers
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...


